Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) has issued an announcement.
NeuroScientific Biopharmaceuticals has initiated treatment for the fourth patient under its Special Access Program using its StemSmart™ MSC therapy for fistulising Crohn’s disease, marking progress towards a Phase 2 clinical trial planned for 2026. This program provides critical real-world data to inform the trial design and offers a potential new therapeutic option for patients with severe, treatment-resistant Crohn’s disease, addressing a significant unmet medical need.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Limited is an Australian biotechnology company focused on developing novel technologies for immune-mediated inflammatory diseases. The company is advancing its patented StemSmart™ mesenchymal stem cell therapy, which is positioned as a platform cell therapy with potential applications in organ transplant immune tolerance, lung inflammatory disease, and graft-vs-host disease.
Average Trading Volume: 343,938
Technical Sentiment Signal: Buy
Current Market Cap: A$46.56M
Find detailed analytics on NSB stock on TipRanks’ Stock Analysis page.